Video

Dr. Ramalingam on Investigating Osimertinib Combination Approaches in NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO, discusses ongoing trials investigating osimertinib combination approaches in non-small cell lung cancer.

Suresh S. Ramalingam, MD, FACP, FASCO, director, Lung Cancer Program, Winship Cancer Institute of Emory University, professor, assistant dean, Roberto C. Goizueta Distinguished Chair for Cancer Research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses ongoing trials investigating osimertinib (Tagrisso) combination approaches in non-small cell lung cancer (NSCLC).

Osimertinib is considered the standard of care in the frontline setting for patients with NSCLC, and by exploring combinations, researchers hope to reduce resistance to the agent, Ramalingam says. The phase 3 FLAURA2 trial (NCT04035486) is examining the chemotherapy with or without osimertinib in the first-line treatment of patients with EGFR-mutated NSCLC, Ramalingam explains.

Additionally, a phase 2 trial (NCT04965090) is exploring combination amivantamab (Rybrevant) and lazertinib (Leclaza) as a first-line therapy in patients with NSCLC harboring EGFR mutations, Ramalingam continues. Another potential combination for osimertinib is the antibody-drug conjugate patritumab deruxtecan (U3-1402), and there are ongoing efforts study the tandem, Ramalingam explains. The key of upcoming research will be to find optimal combinations to improve upon outcomes of osimertinib alone, Ramalingam concludes.

Funding from Daiichi Sanyko. Content Developed Independently by OncLive.

Related Videos
Roger Li, MD, of Moffitt Cancer Center
Michael Deininger, MD, PhD
Shubham Pant, MD, MBBS
Kedar Kirtane, MD
Mazyar Shadman, MD, MPH
Allison Winter, MD, Department of Hematology and Medical Oncology, Cleveland Clinic
Malcolm Mattes, MD, associate professor, Section of Radiation Oncology, Rutgers Robert Wood Johnson Medical School; radiation oncologist, Rutgers Cancer Institute of New Jersey
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology